In an interview on CNBC’s Mad Money, Len Schleifer said Regeneron (REGN) currently has 40 drugs in development representing billions in potential sales. “We know how to make and develop drugs for important conditions,” he noted.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN: